Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 2/20 | 0.56 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | GMNN | O75496 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | THPO | P40225 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | HBB | P68871 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9999640 | 1.00 | DNMT1 (0.56) | DNMT1ADRB1LMNAALDH1A1TP53 | |
| SCHEMBL19059873 | 1.00 | DNMT1 (0.56) | DNMT1ADRB1LMNAALDH1A1TP53 | |
| SCHEMBL10063813 | 1.00 | DNMT1 (0.56) | DNMT1ADRB1LMNAALDH1A1TP53 | |
| SCHEMBL9999665 | 1.00 | DNMT1 (0.56) | DNMT1ADRB1LMNAALDH1A1TP53 | |
| SCHEMBL118662 | 1.00 | DNMT1 (0.56) | DNMT1ADRB1LMNAALDH1A1TP53 | |
| SCHEMBL13376153 | 1.00 | DNMT1 (0.56) | DNMT1ADRB1LMNAALDH1A1TP53 | |
| SCHEMBL118663 | 1.00 | DNMT1 (0.56) | DNMT1ADRB1LMNAALDH1A1TP53 | |
| SCHEMBL10030520 | 0.89 | DNMT1 (0.58) | DNMT1ADRB1LMNAALDH1A1TP53 | |
| SCHEMBL10030514 | 0.89 | DNMT1 (0.58) | DNMT1ADRB1LMNAALDH1A1TP53 | |
| SCHEMBL10064052 | 0.89 | DNMT1 (0.68) | DNMT1ADRB1LMNAALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046457-A1 | PREPARATION OF DECITABINE | DR. REDDY'S LABORATORIES, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| WO-2010129211-A2 | PREPARATION OF DECITABINE | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-11-11 | — | — | WO | disclosed |
| EP-2114152-A1 | USE OF ACETYLATED OR ESTERIFICATED AZACYTIDINE, DECITABINE, OR OTHER NUCLEOSIDE ANALOGS AS ORAL AGENTS FOR THE TREATMENT OF TUMORS OR OTHER DYSPLASTIC SYNDROMES SENSITIVE TO HYPOMETHYLATING AGENTS | Nevada Cancer Institute (US) | 2009-11-11 | — | — | EP | disclosed |
| US-20080182806-A1 | USE OF ACETYLATED OR ESTERIFICATED AZACYTIDINE, DECITABINE, OR OTHER NUCLEOSIDE ANALOGS AS ORAL AGENTS FOR THE TREATMENT OF TUMORS OR OTHER DYSPLASTIC SYNDROMES SENSITIVE TO HYPOMETHYLATING AGENTS | NEVADA CANCER INSTITUTE (US) | 2008-07-31 | — | — | US | disclosed |
| WO-2008092127-A1 | USE OF ACETYLATED OR ESTERIFICATED AZACYTIDINE, DECITABINE, OR OTHER NUCLEOSIDE ANALOGS AS ORAL AGENTS FOR THE TREATMENT OF TUMORS OR OTHER DYSPLASTIC SYNDROMES SENSITIVE TO HYPOMETHYLATING AGENTS | NEVADA CANCER INSTITUTE (US) | 2008-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046457-A1 | PREPARATION OF DECITABINE | DNMT3A, DNMT1, DNMT3B | DNMT1 2/4885ADRB1 4149/4885LMNA 742/4885 |
| US-20080182806-A1 | USE OF ACETYLATED OR ESTERIFICATED AZACYTIDINE, DECITABINE, OR OTHER NUCLEOSIDE ANALOGS AS ORAL AGENTS FOR THE TREATMENT OF TUMORS OR OTHER DYSPLASTIC SYNDROMES SENSITIVE TO HYPOMETHYLATING AGENTS | DCTD, DNMT3A, HDAC5 | DNMT1 5/4885ADRB1 4614/4885LMNA 939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.